Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for amrn
2.94
+0.24 (8.89%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.65 - 2.97
52 week 1.24 - 3.46
Open 2.67
Vol / Avg. 0.00/3.84M
Mkt cap 668.49M
P/E     -
Div/yield     -
EPS -0.53
Shares 205.65M
Beta 1.05
Inst. own 22%
Nov 2, 2016
Q3 2016 Amarin Corporation PLC Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 13, 2016
Amarin Corporation PLC at Rodman & Renshaw Global Investment Conference
Aug 4, 2016
Q2 2016 Amarin Corporation PLC Earnings Release
Aug 4, 2016
Q2 2016 Amarin Corporation PLC Earnings Call
Jul 13, 2016
Amarin Corporation PLC at Cantor Fitzgerald Healthcare Conference - Webcast
Jul 5, 2016
Amarin Corporation PLC Annual Shareholders Meeting (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -40.33% -140.91%
Operating margin -43.47% -118.53%
EBITD margin - -119.11%
Return on average assets -35.67% -67.23%
Return on average equity - -
Employees 210 -
CDP Score - -

Address

Upper Pembroke Pembroke House 2, South Lotts Road
DUBLIN, FK7 9JQ
Ireland
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The Company operates in the business segment of development and commercialization of Vascepa. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its Distributors, that in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. The Company markets Vascepa in the United States.

Officers and directors

Lars G. Ekman M.D. Ph.D. Independent Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 55
Bio & Compensation  - Reuters
Michael Wayne Kalb CPA Chief Financial Officer, Senior Vice President
Age: 45
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Joseph T. Kennedy J.D. Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Age: 52
Bio & Compensation  - Reuters
Michael J. Farrell Vice President - Finance (principal accounting officer and principal financial officer)
Age: 37
Bio & Compensation  - Reuters
Craig B. Granowitz M.D., Ph.D. Chief Medical Officer
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 52
Bio & Compensation  - Reuters
James I. Healy M.D., Ph.D. Non-Executive Independent Director
Age: 51
Bio & Compensation  - Reuters